Anivive Secures Full FDA Approval for Canine Lymphoma Drug Laverdia

The medication, which consists of verdinexor tablets, functions as an XPO1 inhibitor by selectively blocking proteins that allow cancer cells to survive. By transitioning from the conditional approval granted in 2021 to full authorization, the drug is now available for at-home administration, offering pet owners a more accessible alternative to traditional clinical treatments.

Anivive utilized its proprietary platform, AniviveSELECT, to identify verdinexor by cross-referencing human medical data with veterinary biology, while its recruitment tool, AniviveTRIAL, accelerated the pivotal study by managing nearly 40% of patient enrollment. Dechra Veterinary Products holds the rights to distribute the drug in the United States and plans to roll out comprehensive support for clinics later this summer. Following this domestic success, the company is seeking regulatory approval in several international markets, including Canada, Japan, the United Kingdom, and across Europe.